

News Release

Astellas Pharma Inc.
Taiho Pharmaceutical Co., Ltd.

Transfer of Astellas' Fermentation Research-Related Assets to Taiho Pharmaceutical

Tokyo, Japan, January 6, 2014 - Astellas Pharma Inc. (“Astellas”, Tokyo: 4503, President and CEO: Yoshihiko Hatanaka) and Taiho Pharmaceutical Co., Ltd. (“Taiho”, Tokyo, President: Masayuki Kobayashi) announced today that they have concluded an agreement, dated December 27, 2013, to transfer assets related to fermentation research owned by Astellas to Taiho.

1. Objective of the transfer and acquisition

Astellas made a decision to cease in-house fermentation research as part of the reshaping of its research framework in order to enhance its ability to generate innovative drugs (as announced in May 2013), and considered a transfer of its fermentation research-related assets to a third party. Based on a series of its recent management decisions, Astellas will implement a strategic reallocation of resources related to R&D that were previously allocated to fermentation research to further enhance its ability to generate innovative drugs.

Taiho is committed to developing innovative new drugs in areas with high unmet medical needs, particularly in the field of oncology. With this acquisition, Taiho will integrate the fermentation research-related assets into its existing original drug discovery technologies to further strengthen its drug discovery system. Going forward, Taiho will speed up the development of its innovative original drugs through utilization of fermentation technology based on these acquired assets and its existing drug discovery technologies in an integrated manner.

2. Assets subject to the transfer and acquisition

Fermentation library, fermentation research-related facilities and equipment, IT systems, etc.

3. Financial terms

Financial terms of the transaction, including the transfer/acquisition price, are not disclosed.

4. Timetable for the transfer and acquisition

December 27, 2013: Conclusion of agreement on the transfer

March 31, 2014: Due date of the asset transfer (excludes some assets)

5. Corporate Profile (As of March 2013)

Astellas Pharma Inc.

Foundation	1923
Headquarters	2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan
Representative	Yoshihiko Hatanaka, Representative Director, President and CEO
Consolidated Sales	1,005.6 billion yen (Fiscal 2013)
Employees	17,454 (Consolidated basis, March 2013)
Business Description	Manufacturing, marketing and import/export of pharmaceuticals
URL	http://www.astellas.com/en/

Taiho Pharmaceutical Co., Ltd.

Foundation	June 1,1963
Headquarters	1-27 Kandnishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan
Representative	Masayuki Kobayashi, President and Representative Director
Sales	125.0 billion yen (Fiscal 2013)
Employees	2,521 (March 2013)
Business Description	Manufacturing, marketing and import/export of pharmaceuticals, quasi-drugs and medical equipment
URL	http://www.taiho.co.jp/english/

#####